{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:22:51Z","timestamp":1780928571290,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":803,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","journals.elsevierhealth.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ajpath.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T16:48:31Z","timestamp":1502902111000},"page":"2199-2207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures"],"prefix":"10.1016","volume":"187","author":[{"given":"William B.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey K.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2017.08.002_bib1","first-page":"144","article-title":"The pathological classification of human mammary carcinoma: past, present and future","volume":"9","author":"Rosen","year":"1979","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.ajpath.2017.08.002_bib2","first-page":"349","article-title":"Recent progress in the histological typing of human breast tumours","volume":"4","author":"van Bogaert","year":"1981","journal-title":"Diagn Histopathol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib3","article-title":"Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 testing in breast cancer: assessing the value of repeated centralized testing in excision specimens","author":"Hariri","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib4","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1073\/pnas.96.16.9212","article-title":"Distinctive gene expression patterns in human mammary epithelial cells and breast cancers","volume":"96","author":"Perou","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.08.002_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.08.002_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/73432","article-title":"Systematic variation in gene expression patterns in human cancer cell lines","volume":"24","author":"Ross","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2017.08.002_bib7","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.08.002_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ng1038","article-title":"Molecular portraits and the family tree of cancer","volume":"32","author":"Chung","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpath.2017.08.002_bib9","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib10","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.08.002_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2164-7-96","article-title":"The molecular portraits of breast tumors are conserved across microarray platforms","volume":"7","author":"Hu","year":"2006","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ajpath.2017.08.002_bib12","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib13","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.08.002_bib15","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1158\/1078-0432.CCR-04-0667","article-title":"Hypermethylation in histologically distinct classes of breast cancer","volume":"10","author":"Bae","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5","article-title":"Epigenetic silencing of maspin gene expression in human breast cancers","volume":"85","author":"Domann","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.11508","article-title":"DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma","volume":"107","author":"Fackler","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/hmg\/8.3.459","article-title":"Methylation profiling of CpG islands in human breast cancer cells","volume":"8","author":"Huang","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajpath.2017.08.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(98)00021-3","article-title":"Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells","volume":"210","author":"Jhaveri","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.ajpath.2017.08.002_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4161\/epi.1.1.2358","article-title":"DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells","volume":"1","author":"Rivenbark","year":"2006","journal-title":"Epigenetics"},{"key":"10.1016\/j.ajpath.2017.08.002_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yexmp.2007.03.008","article-title":"Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions","volume":"83","author":"Rivenbark","year":"2007","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/labinvest.3700485","article-title":"DNA methylation-dependent silencing of CST6 in human breast cancer cell lines","volume":"86","author":"Rivenbark","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.ajpath.2017.08.002_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1677\/erc.0.0080115","article-title":"DNA methylation in breast cancer","volume":"8","author":"Yang","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib24","first-page":"6178","article-title":"Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer","volume":"63","author":"Yan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib25","first-page":"3105","article-title":"Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers","volume":"61","author":"Dammann","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1011360724350","article-title":"Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer","volume":"6","author":"Widschwendter","year":"2001","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.ajpath.2017.08.002_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/jnci\/92.10.826","article-title":"Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer","volume":"92","author":"Widschwendter","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.08.002_bib28","first-page":"805","article-title":"Methylation of estrogen and progesterone receptor gene 5\u2032 CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors","volume":"2","author":"Lapidus","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib29","first-page":"2552","article-title":"Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells","volume":"54","author":"Ottaviano","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/PAP.0b013e3181a9d4bf","article-title":"Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome","volume":"16","author":"Ross","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib31","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene expression profiling in breast cancer: classification, prognostication, and prediction","volume":"378","author":"Reis-Filho","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2017.08.002_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.breast.2013.01.016","article-title":"Gene expression profiling in breast cancer: a clinical perspective","volume":"22","author":"Arpino","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ajpath.2017.08.002_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13058-015-0514-2","article-title":"Multigene prognostic tests in breast cancer: past, present, future","volume":"17","author":"Gyorffy","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12282-015-0594-y","article-title":"Gene expression-based prognostic and predictive tools in breast cancer","volume":"22","author":"Munkacsy","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000444409","article-title":"Intrinsic subtypes of primary breast cancer: gene expression analysis","volume":"39","author":"Schmidt","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.74","article-title":"Clinical utility of gene-expression signatures in early stage breast cancer","author":"Kwa","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib37","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.08.002_bib38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1373\/clinchem.2006.076497","article-title":"Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer","volume":"53","author":"Cronin","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ajpath.2017.08.002_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/14737159.6.6.803","article-title":"A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX","volume":"6","author":"Kaklamani","year":"2006","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ajpath.2017.08.002_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/14737159.8.2.129","article-title":"Multigene predictors in early-stage breast cancer: moving in or moving out?","volume":"8","author":"Ross","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ajpath.2017.08.002_bib41","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1158\/1078-0432.CCR-04-1707","article-title":"Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy","volume":"11","author":"Esteva","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib42","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.08.002_bib43","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib44","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2008.16.7841","article-title":"Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197","volume":"26","author":"Goldstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib45","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1200\/JCO.2007.14.4501","article-title":"Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features","volume":"26","author":"Goldstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib46","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.08.002_bib47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.08.002_bib48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jso.23933","article-title":"The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score","volume":"111","author":"Alvarado","year":"2015","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2164-7-278","article-title":"Converting a breast cancer microarray signature into a high-throughput diagnostic test","volume":"7","author":"Glas","year":"2006","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ajpath.2017.08.002_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-008-0130-2","article-title":"The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study","volume":"116","author":"Mook","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17530050902751618","article-title":"MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer","volume":"3","author":"Bedard","year":"2009","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.ajpath.2017.08.002_bib52","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djj329","article-title":"Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer","volume":"98","author":"Buyse","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.08.002_bib53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2017.08.002_bib54","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2017.08.002_bib55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ijc.28082","article-title":"A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study","volume":"133","author":"Drukker","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10549-014-2954-2","article-title":"Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms","volume":"145","author":"Drukker","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10549-010-0814-2","article-title":"The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer","volume":"120","author":"Knauer","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib58","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr1399","article-title":"Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay","volume":"8","author":"Perreard","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib59","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","article-title":"Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer","volume":"24","author":"Hess","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib60","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-11-2956","article-title":"Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial","volume":"18","author":"Cheang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib61","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1158\/1078-0432.CCR-12-0286","article-title":"A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen","volume":"18","author":"Chia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-013-2416-2","article-title":"PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer","volume":"138","author":"Martin","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib63","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","article-title":"The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer","volume":"20","author":"Filipits","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.ajpath.2017.08.002_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-14-177","article-title":"Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens","volume":"14","author":"Nielsen","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib67","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-16-2092","article-title":"A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse","volume":"23","author":"Prat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccr.2004.05.015","article-title":"A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen","volume":"5","author":"Ma","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2017.08.002_bib69","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/bcr3038","article-title":"Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer","volume":"13","author":"Jankowitz","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib70","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-07-5026","article-title":"A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer","volume":"14","author":"Ma","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib71","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib72","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mds334","article-title":"EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer","volume":"24","author":"Dubsky","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib73","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib74","doi-asserted-by":"crossref","first-page":"e68252","DOI":"10.1371\/journal.pone.0068252","article-title":"The EndoPredict gene-expression assay in clinical practice: performance and impact on clinical decisions","volume":"8","author":"Muller","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2017.08.002_bib75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1471-2407-6-276","article-title":"Gene expression patterns associated with p53 status in breast cancer","volume":"6","author":"Troester","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2017.08.002_bib76","unstructured":"Coleman WB, Parker JS, Sandhu R, Anders CK: Presence of a p53 mutant gene expression signature associates with poor outcomes among breast cancers. Pathobiology for Investigators, Students, and Academicians [abstract 9.17]. American Society for Investigative Pathology, October 2015"},{"key":"10.1016\/j.ajpath.2017.08.002_bib77","unstructured":"Coleman WB, Parker JS, Sandhu R, Anders CK: Expression of a p53 mutant gene expression signature associates with poor outcomes among ER+\/PR+\/Her2- breast cancers. Pathobiology for Investigators, Students, and Academicians [abstract 9.18]. American Society for Investigative Pathology, October 2015"},{"key":"10.1016\/j.ajpath.2017.08.002_bib78","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.2005.03.2755","article-title":"Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers","volume":"24","author":"Oh","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib79","article-title":"Differential responses to hormone therapy among ER+\/PR+\/HER2- breast cancers that differentially express the estrogen response signature","volume":"29","author":"Sandhu","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2017.08.002_bib80","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.29.1_supplement.926.2","article-title":"Recurrence-free survival among patients with ER+\/PR+\/HER2- breast cancers is predicted by expression of the estrogen response signature","volume":"29","author":"Sandhu","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2017.08.002_bib81","article-title":"Therapeutic benefit of chemotherapy and hormone therapy among estrogen response signature-positive ER+\/PR+\/HER2- breast cancers","volume":"29","author":"Sandhu","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2017.08.002_bib82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djj052","article-title":"Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis","volume":"98","author":"Sotiriou","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2017.08.002_bib83","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2008.18.5934","article-title":"Genomic grade index is associated with response to chemotherapy in patients with breast cancer","volume":"27","author":"Liedtke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-008-0183-2","article-title":"The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy","volume":"116","author":"Zhang","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2017.08.002_bib85","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1158\/1078-0432.CCR-09-1126","article-title":"Activation of host wound responses in breast cancer microenvironment","volume":"15","author":"Troester","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2017.08.002_bib86","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1371\/journal.pbio.0020007","article-title":"Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds","volume":"2","author":"Chang","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ajpath.2017.08.002_bib87","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1073\/pnas.0409462102","article-title":"Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival","volume":"102","author":"Chang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944017306806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944017306806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T07:44:02Z","timestamp":1659339842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944017306806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0002944017306806"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.08.002","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.03.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.05.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.07.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.04.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.04.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}